Fractyl Health, Inc. (NASDAQ:GUTS) Receives $5.40 Average Price Target from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have earned an average rating of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $5.40.

Several equities analysts have weighed in on GUTS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Thursday. Morgan Stanley downgraded Fractyl Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $8.00 to $2.00 in a research report on Thursday, January 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Tuesday, December 2nd.

Hedge Funds Weigh In On Fractyl Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC bought a new stake in shares of Fractyl Health in the 3rd quarter worth about $19,298,000. Alyeska Investment Group L.P. bought a new position in shares of Fractyl Health in the 3rd quarter valued at about $8,981,000. Rosalind Advisors Inc. purchased a new position in Fractyl Health in the third quarter worth about $7,950,000. Woodline Partners LP grew its position in Fractyl Health by 821.1% in the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after acquiring an additional 4,908,693 shares in the last quarter. Finally, General Catalyst Group Management LLC bought a new stake in Fractyl Health during the second quarter worth approximately $7,912,000.

Key Fractyl Health News

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (notably FY2026–FY2030) and trimmed near‑term loss estimates while keeping a “Buy” rating and an $8.00 price target — this signals the analyst expects meaningful recovery and eventual profitability, supporting upside versus the current sub‑$1 trade. HC Wainwright analyst note (MarketBeat)
• Positive Sentiment: Canaccord Genuity reaffirmed a “Buy” rating and an $8.00 price target, echoing the bullish analyst narrative and providing additional third‑party validation of the longer‑term thesis. Canaccord reaffirmation (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call transcript is available — the company recently reported an EPS beat for Q4 (reported EPS vs. consensus), which is supportive but investors will focus on follow‑up cadence, cash runway, and clinical/regulatory catalysts. Q4 2025 earnings call transcript (MSN)
• Negative Sentiment: TipRanks flagged “significant compliance risks” under global anti‑corruption and sanctions laws after a new risk disclosure — legal/compliance issues can slow partnerships, delay commercial progress, or increase remediation costs, creating downside risk and adding near‑term uncertainty. Compliance risk disclosure (TipRanks)

Fractyl Health Price Performance

Shares of GUTS stock opened at $0.45 on Friday. The company’s fifty day simple moving average is $0.71 and its two-hundred day simple moving average is $1.28. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $3.03. The stock has a market cap of $71.17 million, a P/E ratio of -0.24 and a beta of 1.51. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 3.23.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.34. Analysts predict that Fractyl Health will post -1.61 EPS for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.